Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Contraception|October 14, 2008
Medical abortion outcomes after a second dose of misoprostol for persistent gestational sacMatthew F Reeves, Anupa Kudva, Mitchell D Creinin
Scientific Reports|October 20, 2019
Publisher Correction: Novel multiplex PCR-SSP method for centromeric KIR allele discriminationJean-Benoît Le Luduec, Anupa Kudva, Jeanette E Boudreau, et al.
Scientific Reports|October 7, 2018
Novel multiplex PCR-SSP method for centromeric KIR allele discriminationJean-Benoît Le Luduec, Anupa Kudva, Jeanette E Boudreau, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 24, 2010
Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in miceAnupa Kudva, Erich V Scheller, Keven M Robinson, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 6, 2022
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myelomaMaria-Victoria Mateos, Sophie Rigaudeau, Supratik Basu, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 4, 2021
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONEMaria-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
Blood|July 16, 2021
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONEJesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, et al.
BMC Cancer|June 3, 2021
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trialStefan Knop, Maria-Victoria Mateos, Meletios A Dimopoulos, et al.
Lancet (London, England)|December 15, 2019
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Michele Cavo, Joan Blade, et al.
Pageof 1